This company has been acquired
La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !
LogicBio Therapeutics Croissance future
Future contrôle des critères 0/6
Informations clés
n/a
Taux de croissance des bénéfices
-1.2%
Taux de croissance du BPA
| Biotechs croissance des bénéfices | 28.4% |
| Taux de croissance des recettes | -132.5% |
| Rendement futur des capitaux propres | n/a |
| Couverture par les analystes | Low |
| Dernière mise à jour | n/a |
Mises à jour récentes de la croissance future
Recent updates
LogicBio jumps 648% on buyout deal with AstraZeneca unit Alexion
Oct 03Bullish: Analysts Just Made A Notable Upgrade To Their LogicBio Therapeutics, Inc. (NASDAQ:LOGC) Forecasts
Aug 20
LogicBio Therapeutics, Inc. (NASDAQ:LOGC) Just Reported Second-Quarter Earnings And Analysts Are Lifting Their Estimates
Aug 18LogicBio GAAP EPS of -$0.15, revenue of $3.2M
Aug 15Is LogicBio Therapeutics (NASDAQ:LOGC) Weighed On By Its Debt Load?
Jan 11Does LogicBio Therapeutics (NASDAQ:LOGC) Have A Healthy Balance Sheet?
Aug 18LogicBio EPS misses by $0.06, beats on revenue
May 10LogicBio announces agreements with CANbridge Pharma and Daiichi Sankyo
Apr 27Is LogicBio Therapeutics (NASDAQ:LOGC) Using Debt Sensibly?
Apr 12Is LogicBio Therapeutics, Inc. (NASDAQ:LOGC) Popular Amongst Insiders?
Mar 08The LogicBio Therapeutics (NASDAQ:LOGC) Share Price Has Gained 12% And Shareholders Are Hoping For More
Jan 15LogicBio extends collaboration with Children's Medical Research Institute
Jan 07LogicBio Therapeutics names new CFO
Dec 22Looking In On LogicBio
Nov 17LogicBio reports Q3 results
Nov 09Prévisions de croissance des bénéfices et des revenus
| Date | Recettes | Les revenus | Flux de trésorerie disponible | Cash from Op | Moy. Nombre d'analystes |
|---|---|---|---|---|---|
| 12/31/2023 | N/A | N/A | -28 | N/A | 1 |
| 12/31/2022 | 10 | N/A | -27 | N/A | 2 |
| 9/30/2022 | 11 | -27 | -25 | -25 | N/A |
| 6/30/2022 | 10 | -31 | -29 | -28 | N/A |
| 3/31/2022 | 8 | -36 | -22 | -21 | N/A |
| 12/31/2021 | 5 | -40 | -20 | -19 | N/A |
| 9/30/2021 | 4 | -38 | -22 | -21 | N/A |
| 6/30/2021 | 3 | -36 | -17 | -17 | N/A |
| 3/31/2021 | 3 | -33 | -30 | -29 | N/A |
| 12/31/2020 | 3 | -33 | -29 | -29 | N/A |
| 9/30/2020 | 3 | -37 | -34 | -33 | N/A |
| 6/30/2020 | 2 | -40 | -39 | -38 | N/A |
| 3/31/2020 | 1 | -42 | -39 | -38 | N/A |
| 12/31/2019 | N/A | -40 | -40 | -39 | N/A |
| 9/30/2019 | N/A | -32 | -33 | -32 | N/A |
| 6/30/2019 | N/A | -29 | -27 | -26 | N/A |
| 3/31/2019 | N/A | -23 | -21 | -20 | N/A |
| 12/31/2018 | N/A | -18 | -16 | -15 | N/A |
| 9/30/2018 | N/A | -18 | -14 | -13 | N/A |
| 6/30/2018 | N/A | -11 | -11 | -11 | N/A |
| 3/31/2018 | N/A | -9 | -8 | -8 | N/A |
| 12/31/2017 | N/A | -8 | -6 | -6 | N/A |
Prévisions de croissance des analystes
Taux de revenus par rapport au taux d'épargne: Insufficient data to determine if LOGC's forecast earnings growth is above the savings rate (2%).
Bénéfices vs marché: Insufficient data to determine if LOGC's earnings are forecast to grow faster than the US market
Croissance élevée des bénéfices: Insufficient data to determine if LOGC's earnings are expected to grow significantly over the next 3 years.
Chiffre d'affaires vs marché: LOGC's revenue is expected to decline over the next 3 years (-132.5% per year).
Croissance élevée des revenus: LOGC's revenue is forecast to decline over the next 3 years (-132.5% per year).
Prévisions de croissance du bénéfice par action
Rendement futur des capitaux propres
ROE futur: Insufficient data to determine if LOGC's Return on Equity is forecast to be high in 3 years time